Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 avr. 2026 08h15 HE | Source: BCC Research LLC

Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate

Report provides in-depth insights into technological developments, pipeline trends, and global opportunities shaping the future of bispecific antibodies.
09 avr. 2026 08h00 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16th at 4:00 PM ET Register for the event here OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) --...
08 avr. 2026 07h00 HE | Source: Incyclix Bio

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
08 avr. 2026 05h11 HE | Source: Research and Markets

Radiology Information Systems (RIS) Market Set to Double During 2026-2033, Reaching USD 2.64 Billion

Dublin, April 08, 2026 (GLOBE NEWSWIRE) -- The "Radiology Information Systems Market Size, Share & Trends Analysis Report by Product, Deployment Mode, End Use, Region, and Segment Forecasts,...
07 avr. 2026 08h00 HE | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
02 avr. 2026 08h30 HE | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform

LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven...
02 avr. 2026 08h00 HE | Source: Revolution Medicines, Inc.

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
02 avr. 2026 08h00 HE | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
01 avr. 2026 09h00 HE | Source: Access Information Management Shared Services, LLC

Access Recognized by Inc. in its 2026 List of the Fastest Growing Private Companies in the Northeast

PEABODY, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Access, a leading global integrated information management solutions provider, is pleased to announce today that it has been recognized by Inc. in...
01 avr. 2026 08h55 HE | Source: OneMedNet Corporation

OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and A

Page suivante